arrow
B

Bingnan Zhang

The University of Texas MD Anderson Cancer Center
H指数:17
被引数:1,864

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS

多机构关于tarlatamab给药及CRS/ICANS管理的观点

2025-12-060
PRE
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

MET过表达与晚期非小细胞肺癌中更优的免疫治疗效果相关联

2025-11-270
OAAI
Combination Surface Targeting Strategies in Relapsed Small Cell Lung Cancer (SCLC) to Overcome Intratumoral Heterogeneity Associated with Treatment Resistance

在复发小细胞肺癌(SCLC)中结合表面靶向策略以克服与治疗耐药性相关的肿瘤内异质性

2025-08-290
PRE
Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model

利用Brock模型和Sybil模型对持续性肺结节患者进行肺癌风险评估

CANCERS
IF4.4
2025-04-290
OA
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series: Case Report

达拉他单抗在未经治疗的SCLC脑转移患者中快速颅内应答——真实世界病例系列:病例报告

2025-03-240
PRE
Osimertinib with chemotherapy as fi rst-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC): A prospective, multi-centre, real-world study (FOREFRONT)

奥希替尼联合化疗作为一线疗法用于局部晚期或转移性表皮生长因子受体突变(EGFRm)非小细胞肺癌(NSCLC)患者的治疗:一项前瞻性、多中心、真实世界研究(FOREFRONT)

2024-12-010
PRE
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
2024-11-190
OAAI
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets
2024-02-014
OA
YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition
2023-04-040
PRE